COMPANY

Moleculin Biotech

HQ: Houston, TX source · moleculin.com ↗ · Southwest

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. From company website Source · Oct 13, 2026

Keywords: oncology tumors cancer Leukemia, Myeloid, Acute Acute Myeloid Leukaemia Sarcoma,Soft Tissue Pulmonary Metastasis Cutaneous T-Cell Lymphoma/Mycosis Fungoides Liposomal Annamycin WP1122 WP1220

Location: Houston, TX · source · Oct 5, 2026

Profile checked Oct 10, 2026

$5.9MRaised (2 yrs)7Trials (company is sponsor)

Timeline

Jun 20, 2025 Raise Follow-on offering: $5.9M (total, as published), announced Jun 20, 2025. Source: SEC filing. source ↗
Mar 12, 2025 Trial start Phase 2/Phase 3: L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML source ↗
Sep 29, 2022 Trial start Phase 1/Phase 2: Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) source ↗
May 11, 2022 Trial start Phase 1: Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers source ↗
Jun 5, 2021 Trial start Phase 1/Phase 2: Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases source ↗
Mar 8, 2019 Trial start Phase 1: Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) source ↗
Dec 17, 2018 Trial start Phase 1/Phase 2: Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) source ↗
Mar 28, 2018 Trial start Phase 1/Phase 2: Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) source ↗

Upcoming milestones

2029-08 (ESTIMATED) · Phase 2/Phase 3 · L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML · NCT06788756

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $5.9M. Last 2 years.

Jun 20, 2025 Follow-on offering: $5.9M (total, as published), announced Jun 20, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT06788756	L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML	Phase 2/Phase 3	Recruiting	Mar 12, 2025	2029-08 (estimated)
NCT05319587	Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)	Phase 1/Phase 2	Completed	Sep 29, 2022	Aug 2, 2023 (actual)
NCT04887298	Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases	Phase 1/Phase 2	Completed	Jun 5, 2021	Sep 29, 2022 (actual)
NCT05195723	Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers	Phase 1	Completed	May 11, 2022	Oct 24, 2022 (actual)
NCT03388749	Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)	Phase 1/Phase 2	Completed	Dec 17, 2018	Feb 8, 2022 (actual)
NCT03315039	Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)	Phase 1/Phase 2	Completed	Mar 28, 2018	Jan 14, 2020 (actual)
NCT04702503	Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)	Phase 1	Completed	Mar 8, 2019	Nov 15, 2019 (actual)